StockPulse is a software subscription service that translates and summarizes U.S. stock filings and news into alerts. It is not an investment advisory, brokerage, or discretionary management service.

All information provided (filing summaries, price data, keywords, etc.) is processed from public sources for reference only and is not a recommendation to buy or sell any security. Investment decisions and their outcomes are the sole responsibility of the user.

노마드랩 주식회사 · 대표 황승준 · 사업자등록번호 588-81-01342

부산광역시 해운대구 센텀중앙로 55, 9층 7호(우동)

통신판매업 제2026-부산해운대-0983호 · 문의  

고객문의 070-4268-1176

App Store▶ Google Play
GuideFAQWeeklyTerms of ServicePrivacy PolicyPayment & Refund Policy

StockPulse · 스탁펄스(스톡펄스) — 미국주식 공시·뉴스 실시간 알림

© 2026 노마드랩 주식회사. All rights reserved.

StockPulseStockPulseFeedReportMacro·SectorsCommunityAlertsMy
Theme
FeedReportMacro·SectorsCommunityAlertsMy
GELSGelteq Ltd
stockpulse.co.kr
Nasdaq
$0.4303▼ 1.35%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $4.6MShares out 10.7M sh
At a glance🔒 At-a-glance is MAX onlySee plans

Chart

Filings & news by date

Hover (PC) or tap (mobile) a candle to see that day only

🔒 Members only
Live tape🔒 Live tape is MAX onlySee plans

Filings

2
  • 9.18Overnight26.07.03 10:59filed
    6-KKey event#●●●#●●●#●●●

    Gelteq LtdBullish

    Gelteq Limited received shareholder approval on June 18, 2026, for a debt financing agreement totaling up to $3.5 million, subsequently closing a $2.5 million second tranche of convertible notes on June 26, 2026. The notes are convertible at 93% of the volume-weighted average price and include toxic provisions such as balance increases upon trigger events, posing significant dilution risks to shareholders.…more

    $0.4303-1.35%vs prev close
    View filingShare
  • 9.18Overnight26.07.01 10:29filed
    6-KKey event

    Gelteq Ltd

    Gelteq Ltd reported a net loss of 3.74 million AUD for the six-month period ended December 31, 2025. The company has secured a strategic debt financing agreement of up to 3.5 million USD to accelerate clinical programs and plans to commence human clinical trials starting July 1, 2026.…more

    $0.4303-1.35%vs prev close
    View filingShare

1 more filings

Sign up free to unlock the full feed and real-time filing & news alerts.

  • ✓Free — no card required
  • ✓Full real-time filing & news feed
  • ✓Daily Today Report
Sign up free & see allPreview the Today Report →

News

GlobeNewswire

No news collected yet. New articles will appear here.